For research use only. Not for therapeutic Use.
Tirbanibulin（Cat No.:I007320）is a topical microtubule inhibitor used for the treatment of actinic keratosis, a precancerous skin condition caused by prolonged sun exposure. By disrupting microtubule polymerization and inhibiting Src kinase signaling, Tirbanibulin induces apoptosis in abnormal keratinocytes, reducing the risk of progression to squamous cell carcinoma. Its non-invasive, once-daily application over a short treatment period makes it a convenient and effective option for patients. With a favorable safety profile and minimal side effects, Tirbanibulin offers a promising treatment for actinic keratosis and improved skin health.
| Catalog Number | I007320 |
| CAS Number | 897016-82-9 |
| Synonyms | N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide |
| Molecular Formula | C26H29N3O3 |
| Purity | 95% |
| Target Protein | P07437,,, |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | GI50: 9 nM (Src, in HuH7 cells), 13 nM (Src, in PLC/PRF/5 cells), 26 nM (Src, in Hep3B cells), 60 nM (Src, in HepG2 cells) |
| IUPAC Name | N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide |
| InChI | InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30) |
| InChIKey | HUNGUWOZPQBXGX-UHFFFAOYSA-N |
| SMILES | C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4 |
| Reference | [1]. Lau GM, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci, 2009, 54(7), 1465-1474. [2]. Fallah-Tafti A, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem, 2011, 46(10), 4853-4858. |
